| Literature DB >> 20835230 |
Seth L Masters1, Aisling Dunne, Shoba L Subramanian, Rebecca L Hull, Gillian M Tannahill, Fiona A Sharp, Christine Becker, Luigi Franchi, Eiji Yoshihara, Zhe Chen, Niamh Mullooly, Lisa A Mielke, James Harris, Rebecca C Coll, Kingston H G Mills, K Hun Mok, Philip Newsholme, Gabriel Nuñez, Junji Yodoi, Steven E Kahn, Ed C Lavelle, Luke A J O'Neill.
Abstract
Interleukin 1β (IL-1β) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1β. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1β production in vitro. Processing of IL-1β initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1β in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20835230 PMCID： PMC3103663 DOI： 10.1038/ni.1935
Source DB: PubMed Journal: Nat Immunol ISSN： 1529-2908 Impact factor: 25.606